Reminder: Analyst Access: Webinar: AI in Healthcare: Adoption, Execution, and Outcomes in Drug Development

Research evidence excerpt

Reminder: Analyst Access: Webinar: AI in Healthcare: Adoption, Execution, and Outcomes in Drug Development

James Gordon is a Director and Head of the European

Pharma & Biotech Equity Research team at Barclays.

James joined Barclays in November 2025, having spent

c.20 years covering European Pharma & Biotech at J.P.

Morgan, where he was part of a team consistently top

ranked in the Institutional Investor / Extel survey. Prior to

Healthcare Equity Research James worked in Strategy

Consulting, focusing on Pharmaceuticals. James holds a

1st-class BSc in Genetics from University College London,

with a focus on Population Genetics and Statistics.

View Analyst Page

Emily Field, CFA is a Director and Head of U.S.

Biopharmaceuticals equity research at Barclays. Joining

the bank’s London office in 2017, she previously served as

Head of the European Pharmaceuticals team, earning a #4

individual ranking in European Pharmaceuticals &

Biotechnology in the 2025 Extel survey. With more than

two decades experience across both buy-side and sell-side

roles, she has worked across multiple investing strategies

including risk arbitrage and equity long/short. Prior to

Barclays, Ms. Field held positions at UBS O’Connor and

Millennium Management. Originally hailing from Chicago,

Ms. Field holds a B.A. in Economics and History from Yale

University, graduating with distinction in both majors, and

is a CFA charterholder.

Etzer Darout, PhD, MBA, is a Managing Director and equity

research analyst covering the U.S. Small and Mid-Cap

Biotechnology sector, with over 10 years of sell-side

research experience. Before joining Barclays in June 2025,

Etzer spent three years at BMO Capital Markets as a

Managing Director and senior equity research analyst

covering the Biotechnology sector.